Login to Your Account



Secondary school: Spark explains endpoint tweak in gene therapy phase III

By Randy Osborne
Staff Writer

Thursday, September 10, 2015
A new secondary endpoint in the ongoing phase III trial with its gene therapy, SPK-RPE65, “does not represent a change in the trial design or the data collected, simply the way the data from the study are designated for analysis,” Spark Therapeutics Inc. CEO Jeff Marrazzo assured investors Thursday morning.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription